Torch Wealth Management LLC grew its position in shares of Eli Lilly And Co (NYSE:LLY) by 0.8% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 13,413 shares of the company’s stock after buying an additional 100 shares during the quarter. Torch Wealth Management LLC’s holdings in Eli Lilly And Co were worth $1,486,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently bought and sold shares of the company. WP Advisors LLC purchased a new stake in shares of Eli Lilly And Co during the first quarter valued at approximately $38,000. Meridian Wealth Management LLC purchased a new stake in shares of Eli Lilly And Co during the first quarter valued at approximately $38,000. Ellis Investment Partners LLC purchased a new stake in shares of Eli Lilly And Co during the first quarter valued at approximately $39,000. Manchester Financial Inc. purchased a new stake in shares of Eli Lilly And Co during the second quarter valued at approximately $40,000. Finally, Litman Gregory Asset Management LLC purchased a new stake in shares of Eli Lilly And Co during the second quarter valued at approximately $47,000. Hedge funds and other institutional investors own 79.48% of the company’s stock.

LLY stock traded down $0.02 on Thursday, hitting $110.27. The company had a trading volume of 148,956 shares, compared to its average volume of 3,974,435. The company has a current ratio of 1.13, a quick ratio of 0.87 and a debt-to-equity ratio of 4.98. Eli Lilly And Co has a 12-month low of $102.08 and a 12-month high of $132.13. The company has a market capitalization of $109.60 billion, a PE ratio of 19.78, a price-to-earnings-growth ratio of 2.01 and a beta of 0.19. The company has a 50-day moving average of $110.66.

Eli Lilly And Co (NYSE:LLY) last released its quarterly earnings results on Tuesday, July 30th. The company reported $1.50 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.45 by $0.05. Eli Lilly And Co had a net margin of 33.76% and a return on equity of 70.86%. The business had revenue of $5.64 billion for the quarter, compared to the consensus estimate of $5.59 billion. During the same period last year, the firm earned $1.48 earnings per share. The company’s quarterly revenue was up .9% on a year-over-year basis. Analysts anticipate that Eli Lilly And Co will post 5.72 earnings per share for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 10th. Shareholders of record on Thursday, August 15th will be given a $0.645 dividend. The ex-dividend date of this dividend is Wednesday, August 14th. This represents a $2.58 annualized dividend and a yield of 2.34%. Eli Lilly And Co’s payout ratio is presently 46.49%.

In other Eli Lilly And Co news, VP Michael J. Harrington sold 16,000 shares of the stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $116.72, for a total value of $1,867,520.00. Following the transaction, the vice president now directly owns 110,300 shares in the company, valued at $12,874,216. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Joshua L. Smiley purchased 426 shares of the firm’s stock in a transaction on Wednesday, June 5th. The stock was acquired at an average price of $118.03 per share, for a total transaction of $50,280.78. Following the completion of the transaction, the chief financial officer now directly owns 30,410 shares of the company’s stock, valued at approximately $3,589,292.30. The disclosure for this purchase can be found here. 0.11% of the stock is currently owned by company insiders.

LLY has been the topic of a number of recent analyst reports. Cantor Fitzgerald reiterated a “buy” rating and set a $143.00 price target on shares of Eli Lilly And Co in a report on Tuesday, April 30th. Edward Jones upgraded shares of Eli Lilly And Co from a “hold” rating to a “buy” rating and set a $117.49 target price on the stock in a report on Tuesday, April 23rd. Zacks Investment Research cut shares of Eli Lilly And Co from a “buy” rating to a “hold” rating in a report on Tuesday, May 21st. TheStreet cut shares of Eli Lilly And Co from a “b+” rating to a “c+” rating in a report on Thursday, May 9th. Finally, Goldman Sachs Group began coverage on shares of Eli Lilly And Co in a report on Tuesday, May 28th. They issued a “buy” rating and a $135.00 target price on the stock. Nine research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $123.49.

Eli Lilly And Co Company Profile

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Recommended Story: Why do companies issue convertible shares?

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.